Dendritic cells in the pathogenesis and treatment of human diseases: A Janus Bifrons?

Immunotherapy

Volumn 3, Issue 10, 2011, Pages 1203-1222

  Cools, Nathalie ^a   Petrizzo, Annacarmen ^b   Smits, Evelien ^a   Buonaguro, Franco M ^b   Tornesello, Maria L ^b   Berneman, Zwi ^a,c   Buonaguro, Luigi ^b,d  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

autoimmunity; cancer; cell therapy and immunotherapy; dendritic cells; HIV

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ANTIRETROVIRUS AGENT; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; MONOCLONAL ANTIBODY; PROVENGE; TRANSCRIPTION FACTOR;

ALLERGY; AUTOIMMUNITY; BREAST CANCER; CELL DIFFERENTIATION; CELL MATURATION; COLORECTAL CANCER; DENDRITIC CELL; DIABETES MELLITUS; GLIOBLASTOMA; HELPER CELL; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY CANCER; KIDNEY CARCINOMA; LEUKEMIA; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG CANCER; MELANOMA; MYELOID DENDRITIC CELL; NEOPLASM; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; VIRUS INFECTION;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGEN PRESENTATION; AUTOIMMUNITY; CANCER VACCINES; CELL DIFFERENTIATION; DENDRITIC CELLS; HUMANS; HYPERSENSITIVITY; IMMUNOTHERAPY; INFECTION; NEOPLASMS;

EID: 80054118073     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.11.110     Document Type: Review

References (289)

1. Cools N, Ponsaerts P, van Tendeloo VF, Berneman ZN. Balancing between immunity and tolerance: an interplay between dendritic cells,regulatory T cells, and effector T cells. J. Leukoc. Biol. 82(6), 1365-1374 (2007). (Pubitemid 350276946)
2. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 124(4), 783-801 (2006). (Pubitemid 43261452)
3. Pulendran B, Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell 124(4), 849-863 (2006). (Pubitemid 43261457)
4. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu. Rev. Immunol. 21, 335-376 (2003). (Pubitemid 37174535)
5. Germain RN. An innately interesting decade of research in immunology. Nat. Med. 10(12), 1307-1320 (2004). (Pubitemid 40022712)
6. Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature 430(6996), 257-263 (2004). (Pubitemid 38902439)
7. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 20, 197-216 (2002). (Pubitemid 34293424)
8. +r. 58(7), 1149-1157 (2009).
9. Geijtenbeek TB, van Vliet SJ, Engering A, t Hart BA, van Kooyk Y. Self- and nonself-recognition by C-type lectins on dendritic cells. Annu. Rev. Immunol. 22, 33-54 (2004). (Pubitemid 38680417)
10. Inohara N, Chamaillard M, McDonald C, Nunez G. NOD LRR proteins: role in host-microbial interactions and inflammatory disease. Annu. Rev. Biochem. 74, 355-383 (2005). (Pubitemid 40995511)
11. + fountainhead of innate and adaptive immune responses. Cell Stress Chaperones 5(5), 443-451 (2000). (Pubitemid 32057496)
12. Rock KL, Hearn A, Chen CJ, Shi Y. Natural endogenous adjuvants. Springer Semin. Immunopathol. 26(3), 231-246 (2005).
13. Tian J, Avalos AM, Mao SY et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat. Immunol. 8(5), 487-496 (2007). (Pubitemid 46605917)
14. Greenfield EA, Nguyen KA, Kuchroo VK. CD28/B7 costimulation: a review. Crit. Rev. Immunol. 18(5), 389-418 (1998). (Pubitemid 28447017)
15. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14, 233-258 (1996). (Pubitemid 26130184)
16. + immunoregulatory T cells that control autoimmune diabetes. Immunity 12(4), 431-440 (2000).
17. + T cells. J. Immunol. 162(6), 3256-3262 (1999). (Pubitemid 29313572)
18. Curtsinger JM, Lins DC, Mescher MF. Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J. Exp. Med. 197(9), 1141-1151 (2003). (Pubitemid 36570069)
19. +rapy of established cancer: roles of signals 1, 2, 3 and 4 Curr. Opin Investig. Drugs 10(6), 526-535 (2009).
20. +rapeutic cancer vaccines: what we have and what we need. Future Oncol. 5(3), 379-390 (2009).
21. +matosus. Immunol. Res. 37(2), 135-145 (2007). (Pubitemid 47344125)
22. + bronchial mucosa of patients with atopic asthma in response to local allergen challenge. Thorax 56(11), 823-826 (2001).
23. Koido S, Hara E, Homma S et al. Cancer vaccine by fusions of dendritic and cancer cells. Clin. Dev. Immunol. 2009(657369), 1-13 (2009).
24. Palucka K, Banchereau J, Mellman I. Designing vaccines based on biology of human dendritic cell subsets. Immunity 33(4), 464-478 (2010).
25. +rapy. Curr. HIV Res. 8(4), 310-322 (2010).
26. Steinman RM. Dendritic cells in vivo: a key target for a new vaccine science. Immunity 29(3), 319-324 (2008).
27. Steinman RM, Cohn ZA. Identification of a novel cell type I n peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J. Exp. Med. 137(5), 1142-1162 (1973).
28. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 449(7161), 419-426 (2007). (Pubitemid 47509552)
29. +r immature. Immunology 82(3), 487-493 (1994). (Pubitemid 24251635)
30. +ir functions in innate and adaptive immunity. Cell 106(3), 259-262 (2001).
31. Kadowaki N, Ho S, (Pubitemid 32983021)
32. Kohrgruber N, Halanek N, Groger M et al. Survival, maturation, and function of CD11c- and CD11c+ peripheral blood dendritic cells are differentially regulated by cytokines. J. Immunol. 163(6), 3250-3259 (1999). (Pubitemid 29431826)
33. Penna G, Sozzani S, Adorini L. Cutting edge: selective usage of chemokine receptors by plasmacytoid dendritic cells. J. Immunol. 167(4), 1862-1866 (2001). (Pubitemid 32747488)
34. Ju X, Clark G, Hart DN. Review of human DC subtypes. Methods Mol. Biol. 595, 3-20 (2010).
35. Cella M, Jarrossay D, Facchetti F et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat. Med. 5(8), 919-923 (1999). (Pubitemid 29372419)
36. + principal type 1 interferon-producing cells in human blood. Science 284(5421), 1835-1837 (1999).
37. Di Pucchio T., Chatterjee B, Smed- Sorensen A et al. Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I. Nat. Immunol. 9(5), 551-557 (2008). (Pubitemid 351560524)
38. Matsui T, Connolly JE, Michnevitz M et al. CD2 distinguishes two subsets of human plasmacytoid dendritic cells with distinct phenotype and functions. J. Immunol. 182(11), 6815-6823 (2009).
39. MacDonald KP, Munster DJ, Clark GJ, Dzionek A, Schmitz J, Hart DN. Characterization of human blood dendritic cell subsets. Blood 100(13), 4512-4520 (2002). (Pubitemid 35429692)
40. + (BDCA 3)+ dendritic cells (DCs) represent a unique cDC subset that cross-presents necrotic cell antigens. J. Exp. Med. 207(6), 1247-1260 (2010).
41. + leukocytes as putative equivalents of mouse CD8a+ dendritic cells. J. Exp. Med. 207(6), 1261-1271 (2010).
42. + dendritic cells. J. Exp. Med. 207(6), 1273-1281 (2010).
43. + XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8a+ dendritic cells. J. Exp. Med. 207(6), 1283-1292 (2010).
44. Valladeau J, Saeland S. Cutaneous dendritic cells. Semin. Immunol. 17(4), 273-283 (2005). (Pubitemid 40984021)
45. + dermal dendritic cells. Immunity 29(3), 497-510 (2008).
46. Fazilleau N, Mark L, Heyzer-Williams LJ, Heyzer-Williams MG. Follicular helper T cells: lineage and location. Immunity 30(3), 324-335 (2009).
47. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 454(7203), 436-444 (2008).
48. Talmadge JE, Donkor M, Scholar E. Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev. 26(3-4), 373-400 (2007). (Pubitemid 350115102)
49. Shurin MR, Shurin GV, Lokshin A et al. Intratumoral cytokines/chemokines/ growth factors and tumor infiltrating dendritic cells: friends or enemies? Cancer Metastasis Rev. 25(3), 333-356 (2006). (Pubitemid 44922354)
50. + cancer microenvironment. Front. Biosci. 13, 6255-6268 (2008).
51. + tumor, whereas mature dendritic cells are located in peritumoral areas. J. Exp. Med. 190(10), 1417-1426 (1999).
52. +r. 53(11), 978-986 (2004). (Pubitemid 39371742)
53. + invasive margin of colorectal carcinoma. J. Pathol. 196(1), 37-43 (2002).
54. Sandel MH, Dadabayev AR, Menon AG et al. Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin. Cancer Res. 11(7), 2576-2582 (2005).
55. +r. 56(9), 1459-1469 (2007).
56. + clinical prognosis. Cancer 63(3), 496-503 (1989). (Pubitemid 19038466)
57. Coppola D, Fu L, Nicosia SV, Kounelis S, Jones M. Prognostic significance of p53, bcl 2, vimentin, and S100 protein-positive Langerhans cells in endometrial carcinoma. Hum. Pathol. 29(5), 455-462 (1998). (Pubitemid 28213464)
58. Wright-Browne V, McClain KL, Talpaz M, Ordonez N, Estrov Z. Physiology and pathophysiology of dendritic cells. Hum. Pathol. 28(5), 563-579 (1997). (Pubitemid 27213053)
59. Okuyama T, Maehara Y, Kakeji Y, Tsuijitani S, Korenaga D, Sugimachi K. Interrelation between tumor-associated cell surface glycoprotein and host immune response in gastric carcinoma patients. Cancer 82(8), 1468-1475 (1998). (Pubitemid 28164991)
60. + number of intratumoral dendritic cells and z-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer 91(11), 2136-2147 (2001). (Pubitemid 32476379)
61. Eisenthal A, Polyvkin N, Bramante- Schreiber L, Misonznik F, Hassner A, Lifschitz-Mercer B. Expression of dendritic cells in ovarian tumors correlates with clinical outcome in patients with ovarian cancer. Hum. Pathol. 32(8), 803-807 (2001). (Pubitemid 32803980)
62. Iwamoto M, Shinohara H, Miyamoto A et al. Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int. J. Cancer 104(1), 92-97 (2003).
63. Goldman SA, Baker E, Weyant RJ, Clarke MR, Myers JN, Lotze MT. Peritumoral CD1a-positive dendritic cells are associated with improved survival in patients with tongue carcinoma. Arch. Otolaryngol. Head Neck Surg.124(6), 641-646 (1998). (Pubitemid 28272929)
64. Zitvogel L, Terme M, Borg C, Trinchieri G. Dendritic cell-NK cell cross-talk: regulation and physiopathology. Curr. Top. Microbiol. Immunol. 298, 157-174 (2006).
65. + regulation of dendritic cell function. Cytokine Growth Factor Rev. 18(1-2), 5-17 (2007). (Pubitemid 46420546)
66. + induction of adaptive immunity. Immunol. Rev. 227(1), 234-247 (2009).
67. + three Es of cancer immunoediting. Annu. Rev. Immunol. 22, 329-360 (2004).
68. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 4(12), 941-952 (2004). (Pubitemid 39620069)
69. Gottfried E, Kreutz M, Mackensen A. Tumor-induced modulation of dendritic cell function. Cytokine Growth Factor Rev. 19(1), 65-77 (2008). (Pubitemid 351200062)
70. + dendritic cell-tumor cross-talk in cancer. Curr. Opin Immunol. 23(1), 146-152 (2011).
71. Almand B, Resser JR, Lindman B et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res. 6(5), 1755-1766 (2000). (Pubitemid 30305068)
72. Della BS, Gennaro M, Vaccari M et al. Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br. J. Cancer 89(8), 1463-1472 (2003). (Pubitemid 37386601)
73. Vakkila J, Thomson AW, Vettenranta K, Sariola H, Saarinen-Pihkala UM. Dendritic cell subsets in childhood and in children with cancer: relation to age and disease prognosis. Clin. Exp. Immunol. 135(3), 455-461 (2004). (Pubitemid 38297146)
74. (Pubitemid 38196217)
75. (Pubitemid 34633736)
76. + role of reactive oxygen species. J. Leukoc. Biol. 74(2), 186-196 (2003). (Pubitemid 38040415)
77. Perrot I, Blanchard D, Freymond N et al. Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J. Immunol. 178(5), 2763-2769 (2007). (Pubitemid 46333153)
78. +lioma. Celecoxib influences MDSC function. BMC Cancer 10, 464 (2010).
79. Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells in human cancer. Cancer J. 16(4), 348-353 (2010).
80. Sinha P, Clements VK, Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. Journal of Immunology 174(2), 636-645 (2005). (Pubitemid 40094255)
81. +rapy. Mol. Pharm. 8(3), 635-641 (2011).
82. + cell components for induction of suppression. J. Natl Cancer Inst. 69(4), 867-872 (1982). (Pubitemid 13230363)
83. Takeda K, Akira S. Toll-like receptors. Curr. Protoc. Immunol. Chapter 14 (Unit 14), 12 (2007).
84. + Th1/ Th2 paradigm in immunity to infectious diseases. Trends Immunol. 23(9), 450-455 (2002).
85. Moser M, Murphy KM. Dendritic cell regulation of TH1 TH2 development. Nat. Immunol. 1(3), 199-205 (2000).
86. OGarra A, Vieira P.regulatory T cells and mechanisms of immune system control. Nat. Med. 10(8), 801-805 (2004). (Pubitemid 39070850)
87. OGarra A, Robinson D. Development and function of T helper 1 cells. Adv. Immunol. 83, 133-162 (2004). (Pubitemid 38657639)
88. Mowen KA, Glimcher LH. Signaling pathways in Th2 development. Immunol. Rev. 202, 203-222 (2004). (Pubitemid 39576914)
89. + T cell subset inhibits antigen-specific T cell responses and prevents colitis. Nature 389(6652), 737-742 (1997). (Pubitemid 27458961)
90. Allenspach EJ, Lemos MP, Porrett PM, Turka LA, Laufer TM. Migratory and lymphoid-resident dendritic cells cooperate to efficiently prime naive CD4 T cells. Immunity 29(5), 795-806 (2008).
91. Kato H, Sato S, Yoneyama M et al. Cell type-specific involvement of RIG I in antiviral response. Immunity 23(1), 19-28 (2005). (Pubitemid 41019654)
92. +ir fate DC SIGN functions as a pathogen receptor with broad specificity. APMIS 111(7-8), 698-714 (2003). (Pubitemid 37130018)
93. Sevilla N, McGavern DB, Teng C, Kunz S, Oldstone MB. Viral targeting of hematopoietic progenitors and inhibition of DC maturation as a dual strategy for immune subversion. J. Clin. Invest. 113(5), 737-745 (2004). (Pubitemid 38544167)
94. Diaz-San SF, Rodriguez-Calvo T, de Avila A, Sevilla N. Immunosuppression during acute infection with foot-and-mouth disease virus in swine is mediated by IL 10 PLoS ONE 4(5), e5659 (2009).
95. Saito K, it-Goughoulte M, Truscott SM et al. Hepatitis C virus inhibits cell surface expression of HLA DR, prevents dendritic cell maturation, and induces interleukin 10 production. J. Virol. 82(7), 3320-3328 (2008). (Pubitemid 351429910)
96. + NS1 protein. J. Virol. 80(13), 6295-6304 (2006). (Pubitemid 43927432)
97. Yao Y, Li P, Singh P et al. Vaccinia virus infection induces dendritic cell maturation but inhibits antigen presentation by MHC class II. Cell Immunol. 246(2), 92-102 (2007). (Pubitemid 47301780)
98. + cure? Leuk. Lymphoma 51(6), 965-966 (2010).
99. Kittan NA, Bergua A, Haupt S et al. Impaired plasmacytoid dendritic cell innate immune responses in patients with herpes virus-associated acute retinal necrosis. J. Immunol. 179(6), 4219-4230 (2007).
100. Donaghy H, Pozniak A, Gazzard B et al. Loss of blood CD11c(+) myeloid and CD11c(-) plasmacytoid dendritic cells in patients with HIV 1 infection correlates with HIV 1 RNA virus load. Blood 98(8), 2574-2576 (2001).
101. + balance between plasmacytoid DC versus conventional DC determines pulmonary immunity to virus infections. PLoS ONE 3(3), e1720 (2008).
102. Dolganiuc A, Chang S, Kodys K et al. Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN a and plasmacytoid dendritic cell loss in chronic HCV infection. J. Immunol. 177(10), 6758-6768 (2006). (Pubitemid 44715040)
103. Dillon SM, Robertson KB, Pan SC et al. Plasmacytoid and myeloid dendritic cells with a partial activation phenotype accumulate in lymphoid tissue during asymptomatic chronic HIV 1 infection. J. Acquir. Immune Defic. Syndr. 48(1), 1-12 (2008). (Pubitemid 351600852)
104. Boonnak K, Slike BM, Burgess TH et al. Role of dendritic cells in antibody-dependent enhancement of dengue virus infection. J. Virol. 82(8), 3939-3951 (2008). (Pubitemid 351521231)
105. + interplay of herpes simplex virus with dendritic cells. Clin. Exp. Immunol. 142(3), 405-410 (2005). (Pubitemid 41719834)
106. + cellular proteasome. J. Virol. 81(12), 6326-6338 (2007). (Pubitemid 46878039)
107. Granelli-Piperno A, Shimeliovich I, Pack M, Trumpfheller C, Steinman RM. HIV 1 selectively infects a subset of nonmaturing BDCA1-positive dendritic cells in human blood. J. Immunol. 176(2), 991-998 (2006). (Pubitemid 43099698)
108. Granelli-Piperno A, Golebiowska A, Trumpfheller C, Siegal FP, Steinman RM. HIV 1-infected monocyte-derived dendritic cells do not undergo maturation but can elicit IL 10 production and T cell regulation. Proc. Natl Acad. Sci. USA 101(20), 7669-7674 (2004). (Pubitemid 38658087)
109. Weiner HL. A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis. J. Neurol. 255(Suppl. 1), 3-11 (2008). (Pubitemid 351341867)
110. Lukacs-Kornek V, Turley SJ. Self-antigen presentation by dendritic cells and lymphoid stroma and its implications for autoimmunity. Curr. Opin Immunol. 23(1), 138-145 (2011).
111. + pathogenesis of multiple sclerosis. J. Neuroimmunol. 221(1-2), 7-14 (2010).
112. Takahashi K, Honeyman MC, Harrison LC. Impaired yield, phenotype, and function of monocyte-derived dendritic cells in humans at risk for insulin-dependent diabetes. J. Immunol. 161(5), 2629-2635 (1998). (Pubitemid 28397083)
113. + suppressor T cells. Ann. Med. 39(5), 322-334 (2007).
114. Rouse BT. Regulatory T cells in health and disease. J. Intern. Med. 262(1), 78-95 (2007). (Pubitemid 47000634)
115. Cools N, Ponsaerts P, van Tendeloo VF, Berneman ZN. Regulatory T cells and human disease. Clin. Dev. Immunol. 2007, 89195 (2007).
116. Ohnmacht C., Pullner A, King SB, et al. Constitutive ablation of dendritic cells breaks self-tolerance of CD4 T cells and results in spontaneous fatal autoimmunity. J. Exp. Med. 206(3), 549-559 (2009).
117. + severity of relapsing experimental autoimmune encephalomyelitis. J. Immunol. 180(10), 6457-6461 (2008).
118. +r. 8(1), R15 (2006).
119. +r. 7(2), R230-R240 (2005). 120 Lande R, Giacomini E, Serafini B et al. Characterization and recruitment of plasmacytoid dendritic cells in synovial fluid and tissue of patients with chronic inflammatory arthritis. J. Immunol. 173(4), 2815-28
120. Lande R, Giacomini E, Serafini B et al. Characterization and recruitment of plasmacytoid dendritic cells in synovial fluid and tissue of patients with chronic inflammatory arthritis. J. Immunol. 173(4), 2815-2824 (2004). (Pubitemid 39063143)
121. + onset and progression of experimental autoimmune encephalomyelitis. Am. J. Pathol. 157(6), 1991-2002 (2000).
122. + T(H) 17 cells in relapsing EAE. Nat. Immunol. 8(2), 172-180 (2007). (Pubitemid 46152648)
123. + role of dendritic cells in CNS autoimmunity. J. Mol. Med. 88(6), 535-544 (2010).
124. + CNS and play a pathogenic role during autoimmune demyelinating disease. Blood 113(14), 3190-3197 (2009).
125. Gottenberg JE, Cagnard N, Lucchesi C et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogrens syndrome. Proc. Natl Acad. Sci. USA 103(8), 2770-2775 (2006).
126. Boven LA, Montagne L, Nottet HS, De Groot CJ. Macrophage inflammatory protein 1a (MIP 1a), MIP 1b, and RANTES mRNA semiquantification and protein expression in active demyelinating multiple sclerosis (MS) lesions. Clin. Exp. Immunol. 122(2), 257-263 (2000).
127. + CNS, up-regulated in neuroinflammation, active and also inactive multiple sclerosis lesions. J. Neuroimmunol. 190(1-2), 72-79 (2007). (Pubitemid 47625610)
128. Pashenkov M, Teleshova N, Kouwenhoven M et al. Elevated expression of CCR5 by myeloid (CD11c+) blood dendritic cells in multiple sclerosis and acute optic neuritis. Clin. Exp. Immunol. 127(3), 519-526 (2002). (Pubitemid 34437825)
129. Kivisakk P, Mahad DJ, Callahan MK et al. Expression of CCR7 in multiple sclerosis: implications for CNS immunity. Ann. Neurol. 55(5), 627-638 (2004).
130. Barcellos LF, Schito AM, Rimmler JB et al. CC chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Multiple Sclerosis Genetics Group. Immunogenetics 51(4-5), 281-288 (2000). (Pubitemid 30198882)
131. Sellebjerg F, Madsen HO, Jensen CV, Jensen J, Garred P. CCR5 d32, matrix metalloproteinase 9 and disease activity in multiple sclerosis. J. Neuroimmunol. 102(1), 98-106 (2000).
132. + IFN a production induced by apoptotic cells combined with lupus IgG. J. Immunol. 171(6), 3296-3302 (2003). (Pubitemid 37093557)
133. +matosus blood. J. Exp. Med. 197(6), 711-723 (2003). (Pubitemid 36350866)
134. (Pubitemid 351705936)
135. Wildenberg ME, van Helden-Meeuwsen CG, van de Merwe JP, Drexhage HA, Versnel MA. Systemic increase in type I interferon activity in Sjogrens syndrome: a putative role for plasmacytoid dendritic cells. Eur. J. Immunol. 38(7), 2024-2033 (2008).
136. +matosus. Science 294(5546), 1540-1543 (2001). (Pubitemid 33063928)
137. Stasiolek M, Bayas A, Kruse N et al. Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis. Brain 129(Pt 5), 1293-1305 (2006).
138. Bayas A, Stasiolek M, Kruse N, Toyka KV, Selmaj K, Gold R. Altered innate immune response of plasmacytoid dendritic cells in multiple sclerosis. Clin. Exp. Immunol. 157(3), 332-342 (2009).
139. + dysfunctional immune regulation in multiple sclerosis. J. Immunol. 184(9), 5368-5374 (2010).
140. +matosus. J. Immunol. 177(9), 5878-5889 (2006). (Pubitemid 44628801)
141. + pathogenesis of rheumatoid arthritis. J. Leukoc. Biol. 66(2), 286-292 (1999). (Pubitemid 29379170)
142. (Pubitemid 32514523)
143. Karni A, Abraham M, Monsonego A et al. Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J. Immunol. 177(6), 4196-4202 (2006). (Pubitemid 44359955)
144. Huang YM, Stoyanova N, Jin YP et al. Altered phenotype and function of blood dendritic cells in multiple sclerosis are modulated by IFN b and IL 10 Clin. Exp. Immunol. 124(2), 306-314 (2001). (Pubitemid 32587616)
145. +matosus is associated with failure of antigen-presenting cells to express programmed death ligand 1 Rheumatology (Oxford) 47(9), 1335-1341 (2008).
146. Lebre MC, Jongbloed SL, Tas SW, Smeets TJ, McInnes IB, Tak PP. Rheumatoid arthritis synovium contains two subsets of CD83 DC LAMP dendritic cells with distinct cytokine profiles. Am. J. Pathol. 172(4), 940-950 (2008). (Pubitemid 351519991)
147. +r. 10(6), R135 (2008).
148. Vaknin-Dembinsky A, Balashov K, Weiner HL. IL 23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL 23 by antisense oligos increases dendritic cell IL 10 production. J. Immunol. 176(12), 7768-7774 (2006). (Pubitemid 43849078)
149. Vaknin-Dembinsky A, Murugaiyan G, Hafler DA, Astier AL, Weiner HL. Increased IL 23 secretion and altered chemokine production by dendritic cells upon CD46 activation in patients with multiple sclerosis. J. Neuroimmunol. 195(1-2), 140-145 (2008).
150. Jahnsen FL, Lund-Johansen F, Dunne JF, Farkas L, Haye R, Brandtzaeg P. Experimentally induced recruitment of plasmacytoid (CD123high) dendritic cells in human nasal allergy. J. Immunol. 165(7), 4062-4068 (2000). (Pubitemid 32057317)
151. Ohbayashi M, Manzouri B, Flynn T et al. Dynamic changes in conjunctival dendritic cell numbers, anatomical position and phenotype during experimental allergic conjunctivitis. Exp. Mol. Pathol. 83(2), 216-223 (2007). (Pubitemid 47320659)
152. McCarthy NE, Jones HA, Marks NA et al. Inhaled allergen-driven CD1c up-regulation and enhanced antigen uptake by activated human respiratory-tract dendritic cells in atopic asthma. Clin. Exp. Allergy 37(1), 72-82 (2007). (Pubitemid 46011061)
153. Upham JW, Denburg JA, OByrne PM. Rapid response of circulating myeloid dendritic cells to inhaled allergen in asthmatic subjects. Clin. Exp. Allergy 32(6), 818-823 (2002). (Pubitemid 34626076)
154. Bratke K, Lommatzsch M, Julius P et al. Dendritic cell subsets in human bronchoalveolar lavage fluid after segmental allergen challenge. Thorax 62(2), 168-175 (2007).
155. Hagendorens MM, Ebo DG, Schuerwegh AJ et al. Differences in circulating dendritic cell subtypes in cord blood and peripheral blood of healthy and allergic children. Clin. Exp. Allergy 33(5), 633-639 (2003). (Pubitemid 36629688)
156. Shin S, Jang JY, Roh EY et al. Differences in circulating dendritic cell subtypes in pregnant women, cord blood and healthy adult women. J. Korean Med. Sci. 24(5), 853-859 (2009).
157. KleinJan A, Willart M, van Rijt LS et al. An essential role for dendritic cells in human and experimental allergic rhinitis. J. Allergy Clin. Immunol. 118(5), 1117-1125 (2006). (Pubitemid 44666974)
158. + phenotype and function of monocyte-derived dendritic cells in allergic conjunctiva. Br. J. Ophthalmol. 94(12), 1662-1667 (2010).
159. Hagendorens MM, Ebo DG, Bridts CH, De Clerck LS, Stevens WJ. Flow cytometrical determination of regulatory cytokines (IL 10, IL 12) and circulating dendritic cell cytokines in allergic asthmatic children. Cytokine 26(2), 82-88 (2004). (Pubitemid 38410887)
160. + skin. Immunol. Rev. 234(1), 120-141 (2010).
161. Vocanson M, Hennino A, Rozieres A, Poyet G, Nicolas JF. Effector and regulatory mechanisms in allergic contact dermatitis. Allergy 64(12), 1699-1714 (2009).
162. + danger within: endogenous danger signals, atopy and asthma. Clin. Exp. Allergy 39(1), 12-19 (2009).
163. + interface between innate and adaptive immune responses. Allergy 66(5), 579-587 (2011).
164. Trompette A, Divanovic S, Visintin A et al. Allergenicity resulting from functional mimicry of a Toll like receptor complex protein. Nature 457(7229), 585-588 (2009).
165. + development of contact allergy to nickel. Nat. Immunol. 11(9), 814-819 (2010).
166. + establishment of food allergy. Clin. Exp. Allergy 41(6), 890-898 (2011).
167. + characteristic features of asthma. J. Exp. Med. 201(6), 981-991 (2005). (Pubitemid 40524467)
168. de Heer HJ, Hammad H, Soullie T et al. Essential role of lung plasmacytoid dendritic cells in preventing asthmatic reactions to harmless inhaled antigen. J. Exp. Med. 200(1), 89-98 (2004). (Pubitemid 38924731)
169. Koya T, Kodama T, Takeda K et al. Importance of myeloid dendritic cells in persistent airway disease after repeated allergen exposure. Am. J. Respir. Crit. Care Med. 173(1), 42-55 (2006). (Pubitemid 43069787)
170. Palucka K, Banchereau J, Mellman I. Designing vaccines based on biology of human dendritic cell subsets. Immunity 33(4), 464-478 (2010).
171. +rapeutic vaccines against cancer. Nat. Rev. Immunol. 5(4), 296-306 (2005). (Pubitemid 40516155)
172. + T cells to differentiate into CTL. Eur. J. Immunol.37(6), 16781690 (2007). (Pubitemid 46939501)
173. Pace L, Vitale S, Dettori B et al. APC activation by IFN a decreases regulatory T cell and enhances Th cell functions. J. Immunol. 184(11), 5969-5979 (2010).
174. Koski GK, Cohen PA, Roses RE, Xu S, Czerniecki BJ. Reengineering dendritic cell-based anti-cancer vaccines. Immunol. Rev. 222, 256-276 (2008). (Pubitemid 351430379)
175. Mailliard RB, Wankowicz-Kalinska A, Cai Q et al. a type 1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 64(17), 5934-5937 (2004). (Pubitemid 39129387)
176. +rapy. Int. Rev. Immunol. 25(5-6), 377-413 (2006).
177. +rapy for castrationresistant prostate cancer. N. Engl. J. Med.363(5), 411422 (2010).
178. +r. 54(3), 187-207 (2005). (Pubitemid 40174238)
179. Parmiani G, De FA, Novellino L, Castelli C. Unique human tumor antigens: immunobiology and use in clinical trials. J. Immunol. 178(4), 1975-1979 (2007). (Pubitemid 46233392)
180. Buonaguro L, Petrizzo A, Tornesello ML, Buonaguro FM. Translating tumor antigens into cancer vaccines. Clin. Vaccine Immunol. 18(1), 23-34 (2011).
181. + immune system in cancer. Curr. Pharm. Biotechnol. 10(2), 166-184 (2009).
182. +rapy with peptide-based vaccines: what have we achieved? Where are we going? J. Natl Cancer Inst. 94(11), 805-818 (2002). (Pubitemid 34705052)
183. Perez SA, von Hofe E, Kallinteris NL et al. A new era in anticancer peptide vaccines. Cancer 116(9), 2071-2080 (2010).
184. +rapy: moving beyond current vaccines. Nat. Med. 10(9), 909-915 (2004). (Pubitemid 39273730)
185. + T cells in patients with melanoma. J. Immunol. 175(9), 6169-6176 (2005). (Pubitemid 41508105)
186. Palucka K, Ueno H, Fay J, Banchereau J. Dendritic cells and immunity against cancer. J. Intern. Med. 269(1), 64-73 (2011).
187. Palucka K, Ueno H, Zurawski G, Fay J, Banchereau J. Building on dendritic cell subsets to improve cancer vaccines. Curr. Opin Immunol. 22(2), 258-263 (2010).
188. Mohamadzadeh M, Berard F, Essert G et al. Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells. J. Exp. Med. 194(7), 1013-1020 (2001).
189. +rapy protocols in cancer. Curr. Mol. Med. 9(6), 725-731 (2009).
190. +rapy. Eur. J. Cancer 45(8), 1424-1431 (2009).
191. +rapy by dendritic cells. Immunity 29(3), 372-383 (2008).
192. + tumor microenvironment. Clin. Cancer Res. 15(21), 6476-6478 (2009).
193. Kaneno R, Shurin GV, Tourkova IL, Shurin MR. Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations. J. Transl Med. 7, 58 (2009).
194. +rapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL 12-dependent mechanism. J. Immunol. 183(1), 137-144 (2009).
195. Casares N, Pequignot MO, Tesniere A et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 202(12), 1691-1701 (2005). (Pubitemid 41815875)
196. + balance of dendritic cell subsets in lymphoid organs. Blood 115(22), 4384-4392 (2010).
197. Wada S, Yoshimura K, Hipkiss EL et al. Cyclophosphamide augments antitumor immunity: studies in an autocht honous prostate cancer model. Cancer Res. 69(10), 4309-4318 (2009).
198. +rapy of cancer. Blood 95(6), 2024-2030 (2000). (Pubitemid 30151641)
199. +r. 3(1), 77-84 (2001).
200. + treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893 Clin. Orthop. Relat. Res. (262), 3-11 (1991).
201. +rapy drugs that could cure cancers. Immunol. Rev. 222, 357-368 (2008). (Pubitemid 351430366)
202. + innate immune system. Science 327(5963), 291-295 (2010).
203. + T cell-mediated suppression by dendritic cells. Science 299(5609), 1033-1036 (2003). (Pubitemid 36222922)
204. +r. 58(4), 575-587 (2009).
205. Stary G, Bangert C, Tauber M, Strohal R, Kopp T, Stingl G. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J. Exp. Med. 204(6), 1441-1451 (2007). (Pubitemid 46919881)
206. +rapy of malignant melanoma: summary of a seven-year experience. Ann. Surg. 180(4), 635-643 (1974).
207. + bladder. Regression following intratumor injection of BCG vaccine. JAMA 229(6), 688 (1974).
208. + bladder. N. Engl. J. Med. 325(17), 1205-1209 (1991).
209. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imi (Pubitemid 38580549)
210. +rapy 1(6), 949-964 (2009).
211. Banchereau J, Klechevsky E, Schmitt N, Morita R, Palucka K, Ueno H. Harnessing human dendritic cell subsets to design novel vaccines. Ann. NY Acad. Sci. 1174, 24-32 (2009).
212. +rapy by stimulation in vitro with HIV 1 protein-loaded dendritic cells. J. Virol. 75(9), 4413-4419 (2001). (Pubitemid 32410155)
213. Lu W, Andrieu JM. In vitro human immunodeficiency virus eradication by autologous CD8(+) T cells expanded with inactivated-virus-pulsed dendritic cells. J. Virol. 75(19), 8949-8956 (2001). (Pubitemid 32851899)
214. Zhao XQ, Huang XL, Gupta P et al. Induction of anti-human immunodeficiency virus type 1 (HIV 1) CD8(+) and CD4(+) T cell reactivity by dendritic cells loaded with HIV 1 X4-infected apoptotic cells. J. Virol. 76(6), 3007-3014 (2002). (Pubitemid 34184885)
215. +rapies for human immunodeficiency virus. Trends Immunol. 32(3), 131-137 (2011).
216. +r. 9(4), 353-363 (2007). (Pubitemid 47255668)
217. +rapy in HIV-infected patients. AIDS Res. Hum. Retroviruses 14(7), 551-560 (1998). (Pubitemid 28196782)
218. +rapeutic dendritic-cell vaccine for chronic HIV 1 infection. Nat. Med. 10(12), 1359-1365 (2004). (Pubitemid 40022718)
219. Andrieu JM, Lu W. A dendritic cell-based vaccine for treating HIV infection: background and preliminary results. J. Intern. Med. 261(2), 123-131 (2007). (Pubitemid 46090321)
220. +rapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV 1 in patients with chronic HIV 1 infection. J. Infect. Dis. 191(10), 1680-1685 (2005). (Pubitemid 40656756)
221. +rapeutic immunization with human immunodeficiency virus type 1 (HIV 1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV 1-infected individuals. Clin. Vaccine Immunol. 15(2), 284-292 (2008). (Pubitemid 352025534)
222. +rapy. Clin. Immunol. 134(2), 140-147 (2010).
223. +rapeutic dendritic cell vaccine. J. Immunol. Methods 365(1-2), 27-37 (2011).
224. Hawiger D, Inaba K, Dorsett Y et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194(6), 769-779 (2001). (Pubitemid 32983013)
225. + T cell tolerance. J. Exp. Med. 196(12), 1627-1638 (2002). (Pubitemid 36026474)
226. +r diseases. Transplant Proc. 30(8), 4126-4127 (1998). (Pubitemid 29013179)
227. Victor FC, Gottlieb AB, Menter A. Changing paradigms in dermatology: tumor necrosis factor a (TNF a) blockade in psoriasis and psoriatic arthritis. Clin. Dermatol. 21(5), 392-397 (2003). (Pubitemid 37543555)
228. Mannon PJ, Fuss IJ, Mayer L et al. Anti-interleukin 12 antibody for active Crohns disease. N. Engl. J. Med. 351(20), 2069-2079 (2004). (Pubitemid 39482500)
229. + treatment of psoriasis. N. Engl. J. Med. 356(6), 580-592 (2007). (Pubitemid 46220818)
230. Leonardi CL, Kimball AB, Papp KA et al. Efficacy and safety of ustekinumab, a human interleukin 12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371(9625), 1665-1674 (2008). (Pubitemid 351671883)
231. Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a Phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 7(9), 796-804 (2008).
232. Ettmayer P, Mayer P, Kalthoff F et al. A novel low molecular weight inhibitor of dendritic cells and B cells blocks allergic inflammation. Am. J. Respir. Crit. Care Med.173(6), 599-606 (2006). (Pubitemid 43363800)
233. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. 193(2), 233-238 (2001). (Pubitemid 32524454)
234. Dhodapkar MV, Steinman RM. Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans. Blood 100(1), 174-177 (2002). (Pubitemid 35177444)
235. + quest for transplant tolerance. Nat. Rev. Immunol. 7(8), 610-621 (2007). (Pubitemid 47123548)
236. Penna G, Amuchastegui S, Giarratana Net al. 1,25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoiddendritic cells. J. Immunol. 178(1), 145153 (2007). (Pubitemid 46033595)
237. + phagocytosed necrotic cellular fragments. Cell Immunol. 215(2), 186-194 (2002).
238. Steinbrink K, Graulich E, Kubsch S, Knop J, Enk AH. CD4(+) and CD8(+) anergic T cells induced by interleukin 10-treated human dendritic cells display antigen-specific suppressor activity. Blood 99(7), 2468-2476 (2002). (Pubitemid 34525434)
239. Geissmann F, Revy P, Brousse N et al. Retinoids regulate survival and antigen presentation by immature dendritic cells. J. Exp. Med. 198(4), 623-634 (2003). (Pubitemid 37040396)
240. Rutella S, Danese S, Leone G. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood 108(5), 1435-1440 (2006). (Pubitemid 44316106)
241. Gonzalez-Rey E, Chorny A, Fernandez-Martin A, Ganea D, Delgado M. Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells. Blood 107(9), 3632-3638 (2006).
242. +rapeutic tolerogenic dendritic cells for rheumatoid arthritis. Ann. Rheum Dis. 69(11), 2042-2050 (2010).
243. +rapy for autoimmunity. Int. Rev. Immunol. 29(2), 156-183 (2010).
244. + cell biology of antigen presentation. Curr. Opin Immunol. 20(1), 89-95 (2008).
245. + DEC 205 receptor improves T cell vaccination. J. Exp. Med. 199(6), 815-824 (2004). (Pubitemid 38375201)
246. Wei H, Wang S, Zhang D et al. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice. Clin. Cancer Res. 15(14), 4612-4621 (2009).
247. Nagayama H, Sato K, Morishita M et al. Results of a Phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin 2 Melanoma Res. 13(5), 521-530 (2003). (Pubitemid 37266955)
248. +r. 55(7), 819-829 (2006).
249. +r. 31(1), 101-112 (2008). (Pubitemid 351619409)
250. Lopez MN, Pereda C, Segal G et al. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor b-expressing T cells. J. Clin. Oncol. 27(6), 945-952 (2009).
251. Ribas A, Camacho LH, Lee SM et al. Multicenter Phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma. J. Transl Med. 8, 89 (2010).
252. + vaccine and of IL 10 1082 promoter genotype as predictor of disease progression. J. Transl Med. 6, 6 (2008).
253. +rapy with dendritic cells pulsed by autologous dactinomycin-induced melanoma apoptotic bodies for patients with malignant melanoma. Melanoma Res. 19(5), 309-315 (2009).
254. + immunity. Clin. Cancer Res. 11(21), 7692-7699 (2005). (Pubitemid 41611611)
255. +r. 60(2), 249-260 (2011).
256. Lesimple T, Neidhard EM, Vignard V et al. Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients. Clin. Cancer Res. 12(24), 7380-7388 (2006). (Pubitemid 46095412)
257. Ribas A, Comin-Anduix B, Chmielowski B et al. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin. Cancer Res. 15(19), 6267-6276 (2009).
258. Avigan D, Vasir B, Gong J et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin. Cancer Res. 10(14), 4699-4708 (2004). (Pubitemid 38955520)
259. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. Induction of cytotoxic T lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96(9), 3102-3108 (2000).
260. +r. 10(6), 983-991 (2010).
261. Um SJ, Choi YJ, Shin HJ et al. Phase I study of autologous dendritic cell tumor vaccine in patients with non-small cell lung cancer. Lung Cancer 70(2), 188-194 (2010).
262. Hirschowitz EA, Foody T, Hidalgo GE, Yannelli JR. Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells. Lung Cancer 57(3), 365-372 (2007). (Pubitemid 47285427)
263. Chang GC, Lan HC, Juang SH et al. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma. Cancer 103(4), 763-771 (2005).
264. +r. 30(7), 749-761 (2007). (Pubitemid 47480758)
265. +rapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma. Clin. Immunol. 125(3), 257-267 (2007). (Pubitemid 350116707)
266. +rapy in metastatic renal cell carcinoma patients. Clin. Cancer Res. 15(15), 4986-4992 (2009).
267. +r. 26(5), 412-419 (2003). (Pubitemid 37128553)
268. +r. 55(1), 63-67 (2006). (Pubitemid 41783295)
269. Burgdorf SK. Dendritic cell vaccination of patients with metastatic colorectal cancer. Dan. Med. Bull. 57(9), B4171 (2010).
270. +rapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest. 21(3), 341-349 (2003). (Pubitemid 37055665)
271. Morse MA, Clay TM, Hobeika AC et al. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin. Cancer Res. 11(8), 3017-3024 (2005). (Pubitemid 40525207)
272. Liu KJ, Wang CC, Chen LT et al. Generation of carcinoembryonic antigen (CEA)-specific T cell responses in HLA A.*0201 and HLA A.*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides. Clin. Cancer Res. 10(8), 2645-2651 (2004).
273. +r. 52(3), 155-161 (2003). (Pubitemid 36384715)
274. +r. 28(5), 496-504 (2005).
275. +rapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology 49(1), 124-132 (2009).
276. Yamanaka R, Homma J, Yajima N et al Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical Phase I/II trial. Clin. Cancer Res. 11(11), 41604167 (2005).
277. + cytotoxic T cells in patients with malignant glioma. J. Neurooncol. 72(2), 107-113 (2005). (Pubitemid 40796460)
278. + local central nervous system tumor microenvironment. Clin. Cancer Res. 11(15), 5515-5525 (2005). (Pubitemid 41060828)
279. + T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {a} type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J. Clin. Oncol. 29(3), 330-336 (2011).
280. +rapy 8(3), 290-298 (2006). (Pubitemid 43947794)
281. Westermann J, Kopp J, van Lessen A et al. Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia. Br. J. Haematol. 137(4), 297-306 (2007). (Pubitemid 46650246)
282. +regulatory T cells toward an antileukemia response. Leukemia 22(5), 1007-1017 (2008). (Pubitemid 351689883)
283. van Tendeloo VF, van de Velde A, van Driessche A et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms tumor 1 antigen-targeted dendritic cell vaccination. Proc. Natl Acad. Sci. USA 107(31), 13824-13829 (2010).
284. +rapeutic effect of autologous dendritic cell vaccine on patients with chronic hepatitis B: a clinical study. World J. Gastroenterol. 11(12), 1806-1808 (2005). (Pubitemid 40520773)
285. Luo J, Li J, Chen RL et al. Autologus dendritic cell vaccine for chronic hepatitis B carriers: a pilot, open label, clinical trial in human volunteers. Vaccine 28(13), 2497-2504 (2010).
286. +rapy in HCV-infected individuals. J. Hepatol. 53(4), 599-607 (2010).
287. Grigoleit GU, Kapp M, Hebart H et al. Dendritic cell vaccination in allogeneic stem cell recipients: induction of human cytomegalovirus (HCMV)-specific cytotoxic T lymphocyte responses even in patients receiving a transplant from an HCMV-seronegative donor. J. Infect. Dis. 196(5), 699-704 (2007). (Pubitemid 47293851)
288. +rapeutic dendritic cell-based vaccine for HIV 1 infection. J. Infect. Dis. 203(4), 473-478 (2011).
289. +rapy. Vaccine 27(43), 6088-6094 (2009).